| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
For individuals affected by cardiovascular disease, genetic testing can identify underlying heritable causes, confirm a diagnosis, and provide insights on prognosis, clinical management, and risk of recurrence. Genetic testing can also help providers understand the need for additional screening recommendations for patients and family members.
Mayo Clinic Laboratories’ cardiovascular genetic testing is among the most comprehensive diagnostic testing available and includes multiple disease-focused panels comprising over 300 genes. Our full suite of cardiogenetic panels was developed to align with expert consensus guidelines on genetic testing for hereditary cardiovascular disease.1-6 Results from our testing can facilitate gene-based management strategies, such as surgical interventions and pharmacologic management, as well as support familial cascade testing when a reportable variant is detected.
More information
Our integration with the clinical cardiology practice at Mayo Clinic translates into the development of high-quality, clinically useful tests backed by unparalleled experience and expertise. In addition, the engagement of laboratory genetic counselors in case review and result interpretation ensures patients receive the right test and providers receive clear interpretations correlated with their patient’s personal medical history.
Our panels for hereditary cardiomyopathy and cardiac arrhythmia offer both disease-specific and comprehensive testing options.
Key testing
Highlights
In this month's "Hot Topic," Linnea Baudhuin, Ph.D., discusses Mayo Clinic Laboratories’ up-to-date gene panel tests for cardiomyopathies and arrhythmias, connective tissue and vascular fragility disorders, dyslipidemias, and congenital heart disease.
Genetic testing for thoracic aortic disease and other forms of connective tissue disease can differentiate among Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, heritable thoracic aortic disease/aortopathy, and related conditions with overlapping clinical presentations.
Key testing
The genetics of dyslipidemia can be complex, and these conditions are often underdiagnosed. Our gene panels aid in the diagnosis of patients with both common and rare forms of dyslipidemia.
Key testing
These tests are unique in their ability to evaluate postmortem tissue samples for underlying genetic causes of sudden cardiac death.
Key testing
Highlights
Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC, describe how Mayo Clinic Laboratories' postmortem genetic tests can provide answers after a sudden unexplained cardiac death. Test results are important for managing family members' risk for cardiovascular disease.
For over two decades, Mayo Clinic has been at the forefront of cardiovascular (CV) genetic testing. The current test menu features 24 different panels that span over 300 genes linked to inherited cardiovascular disorders, many of which are rare and challenging to diagnose. Whereas many labs operate in a “silo” — meaning they take a genetic specimen, test it, and then return a result with limited input — Mayo Clinic takes a much more expansive approach.
Congenital heart disease (CHD) impacts approximately 1% of live births and may be isolated (nonsyndromic) or part of a systemic condition involving additional congenital anomalies (syndromic). Genetic testing can assist in identifying the cause of CHD.
Key testing